← All trials
NCT05206370
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 20, 2022
- Primary completion
- Jan 31, 2023
- Completion date
- Jan 31, 2023
- First posted
- Jan 25, 2022
- Last posted
- Sep 28, 2022
- Enrollment
- 750
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Achieve Life SciencesLead sponsor
- Achieve Life SciencesStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.